Compare · NYXH vs SYK
NYXH vs SYK
Side-by-side comparison of Nyxoah SA (NYXH) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NYXH and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 772.6x NYXH ($164.1M).
- Over the past year, NYXH is down 74.6% and SYK is down 16.2% - SYK leads by 58.3 points.
- SYK has been more active in the news (9 items in the past 4 weeks vs 4 for NYXH).
- SYK has more recent analyst coverage (25 ratings vs 9 for NYXH).
- Company
- Nyxoah SA
- Stryker Corporation
- Price
- $1.63+1.24%
- $330.59+0.86%
- Market cap
- $164.1M
- $126.81B
- 1M return
- +15.60%
- -1.81%
- 1Y return
- -74.57%
- -16.24%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 9
- Recent ratings
- 9
- 25
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest NYXH
- Information on the total number of voting rights and shares
- Amendment: SEC Form SCHEDULE 13G/A filed by Nyxoah SA
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
- Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Announces Preliminary Results for the Second Quarter of 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Nyxoah SA
- Information on the total number of voting rights and shares
- Publication relating to transparency notifications
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation